Do analysts recommend YDES or PHAR?

Pharming Group has a consensus price target of $38.67, suggesting a potential upside of 288.61%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pharming Group 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has preferable earnings and valuation, YDES or PHAR?

Pharming Group has higher revenue and earnings than YD Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Pharming Group $376.13M 1.87 $2.85M $0.12 82.92

Does the media refer more to YDES or PHAR?

In the previous week, Pharming Group had 14 more articles in the media than YD Bio. MarketBeat recorded 15 mentions for Pharming Group and 1 mentions for YD Bio. Pharming Group's average media sentiment score of 0.38 beat YD Bio's score of 0.21 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate DBVT or YDES?

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 332.65%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe DBV Technologies is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, DBVT or YDES?

YD Bio has lower revenue, but higher earnings than DBV Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DBV Technologies $5.64M 124.98 -$146.95M -$3.51 N/A YD Bio N/A N/A N/A N/A N/A

Is DBVT or YDES more profitable?

YD Bio has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. YD Bio's return on equity of 0.00% beat DBV Technologies' return on equity. Company Net Margins Return on Equity Return on Assets DBV Technologies -3,506.53% -119.33% -84.43% YD Bio N/A N/A N/A

Does the media refer more to DBVT or YDES?

In the previous week, DBV Technologies had 10 more articles in the media than YD Bio. MarketBeat recorded 11 mentions for DBV Technologies and 1 mentions for YD Bio. DBV Technologies' average media sentiment score of 0.29 beat YD Bio's score of 0.21 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate YDES or ANNX?

Annexon has a consensus price target of $15.29, suggesting a potential upside of 271.01%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Annexon 2 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation & earnings, YDES or ANNX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Annexon N/A N/A -$206.69M -$1.16 N/A

Is YDES or ANNX more profitable?

YD Bio's return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Annexon N/A -106.15% -79.82%

Does the media refer more to YDES or ANNX?

In the previous week, Annexon had 9 more articles in the media than YD Bio. MarketBeat recorded 10 mentions for Annexon and 1 mentions for YD Bio. Annexon's average media sentiment score of 1.02 beat YD Bio's score of 0.21 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate VSTM or YDES?

Verastem presently has a consensus target price of $13.83, suggesting a potential upside of 75.11%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts plainly believe Verastem is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Verastem 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, VSTM or YDES?

YD Bio has lower revenue, but higher earnings than Verastem. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verastem $30.91M 23.15 -$209.47M -$2.66 N/A YD Bio N/A N/A N/A N/A N/A

Is VSTM or YDES more profitable?

YD Bio has a net margin of 0.00% compared to Verastem's net margin of -231.59%. YD Bio's return on equity of 0.00% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Verastem -231.59% -467.49% -94.54% YD Bio N/A N/A N/A

Does the media refer more to VSTM or YDES?

In the previous week, Verastem had 6 more articles in the media than YD Bio. MarketBeat recorded 7 mentions for Verastem and 1 mentions for YD Bio. YD Bio's average media sentiment score of 0.21 beat Verastem's score of -0.06 indicating that YD Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verastem 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NVCT or YDES?

Nuvectis Pharma presently has a consensus price target of $36.25, indicating a potential upside of 74.95%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvectis Pharma is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvectis Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NVCT or YDES?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A YD Bio N/A N/A N/A N/A N/A

Is NVCT or YDES more profitable?

YD Bio's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% YD Bio N/A N/A N/A

Does the media refer more to NVCT or YDES?

In the previous week, Nuvectis Pharma had 4 more articles in the media than YD Bio. MarketBeat recorded 5 mentions for Nuvectis Pharma and 1 mentions for YD Bio. Nuvectis Pharma's average media sentiment score of 0.32 beat YD Bio's score of 0.21 indicating that Nuvectis Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral YD Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

YD Bio (YDES) Competitors

$7.81 +0.39 (+5.26%)

Closing price 04:00 PM Eastern

Extended Trading

$7.92 +0.11 (+1.41%)

As of 06:38 PM Eastern

Compare

YDES vs. PHAR, DBVT, ANNX, VSTM, and NVCT

Should you buy YD Bio stock or one of its competitors? YD Bio's main competitors and comparable companies include Pharming Group (PHAR), DBV Technologies (DBVT), Annexon (ANNX), Verastem (VSTM), and Nuvectis Pharma (NVCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does YD Bio compare to Pharming Group?

YD Bio (NASDAQ:YDES) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

0.0% of Pharming Group shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharming Group has higher revenue and earnings than YD Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Pharming Group	$376.13M	1.87	$2.85M	$0.12	82.92

In the previous week, Pharming Group had 14 more articles in the media than YD Bio. MarketBeat recorded 15 mentions for Pharming Group and 1 mentions for YD Bio. Pharming Group's average media sentiment score of 0.38 beat YD Bio's score of 0.21 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Pharming Group has a net margin of 2.51% compared to YD Bio's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat YD Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Pharming Group	2.51%	3.40%	1.90%

Pharming Group has a consensus price target of $38.67, suggesting a potential upside of 288.61%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Pharming Group beats YD Bio on 11 of the 11 factors compared between the two stocks.

How does YD Bio compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

In the previous week, DBV Technologies had 10 more articles in the media than YD Bio. MarketBeat recorded 11 mentions for DBV Technologies and 1 mentions for YD Bio. DBV Technologies' average media sentiment score of 0.29 beat YD Bio's score of 0.21 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	1 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DBV Technologies presently has a consensus target price of $48.50, suggesting a potential upside of 332.65%. Given DBV Technologies' stronger consensus rating and higher possible upside, equities research analysts clearly believe DBV Technologies is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

YD Bio has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. YD Bio's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
YD Bio	N/A	N/A	N/A

YD Bio has lower revenue, but higher earnings than DBV Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	124.98	-$146.95M	-$3.51	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

71.7% of DBV Technologies shares are held by institutional investors. 1.1% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

DBV Technologies beats YD Bio on 8 of the 11 factors compared between the two stocks.

How does YD Bio compare to Annexon?

YD Bio (NASDAQ:YDES) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Annexon had 9 more articles in the media than YD Bio. MarketBeat recorded 10 mentions for Annexon and 1 mentions for YD Bio. Annexon's average media sentiment score of 1.02 beat YD Bio's score of 0.21 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annexon	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

YD Bio's return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Annexon	N/A	-106.15%	-79.82%

Annexon has a consensus price target of $15.29, suggesting a potential upside of 271.01%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Annexon	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A

Summary

Annexon beats YD Bio on 5 of the 7 factors compared between the two stocks.

How does YD Bio compare to Verastem?

Verastem (NASDAQ:VSTM) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

YD Bio has lower revenue, but higher earnings than Verastem.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verastem	$30.91M	23.15	-$209.47M	-$2.66	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

YD Bio has a net margin of 0.00% compared to Verastem's net margin of -231.59%. YD Bio's return on equity of 0.00% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verastem	-231.59%	-467.49%	-94.54%
YD Bio	N/A	N/A	N/A

88.4% of Verastem shares are held by institutional investors. 1.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Verastem presently has a consensus target price of $13.83, suggesting a potential upside of 75.11%. Given Verastem's stronger consensus rating and higher possible upside, equities research analysts plainly believe Verastem is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verastem	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Verastem had 6 more articles in the media than YD Bio. MarketBeat recorded 7 mentions for Verastem and 1 mentions for YD Bio. YD Bio's average media sentiment score of 0.21 beat Verastem's score of -0.06 indicating that YD Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verastem	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Verastem beats YD Bio on 7 of the 11 factors compared between the two stocks.

How does YD Bio compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Nuvectis Pharma presently has a consensus price target of $36.25, indicating a potential upside of 74.95%. Given Nuvectis Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Nuvectis Pharma is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

96.8% of Nuvectis Pharma shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Nuvectis Pharma had 4 more articles in the media than YD Bio. MarketBeat recorded 5 mentions for Nuvectis Pharma and 1 mentions for YD Bio. Nuvectis Pharma's average media sentiment score of 0.32 beat YD Bio's score of 0.21 indicating that Nuvectis Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
YD Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

YD Bio's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
YD Bio	N/A	N/A	N/A

Summary

Nuvectis Pharma beats YD Bio on 8 of the 10 factors compared between the two stocks.

Get YD Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YDES and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YDES vs. The Competition

Export

Metric	YD Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$552.87M	$3.86B	$7.12B	$13.07B
Dividend Yield	N/A	3.63%	2.52%	14.40%
P/E Ratio	N/A	13.52	273.58	25.81
Price / Sales	N/A	1,290.27	654.47	104.92
Price / Cash	N/A	120.99	79.75	52.18
Price / Book	N/A	15.66	10.51	6.26
Net Income	N/A	-$22.67M	$3.50B	$360.95M
7 Day Performance	63.73%	-3.44%	-2.48%	-1.89%
1 Month Performance	106.61%	-9.35%	-5.65%	-3.43%
1 Year Performance	N/A	22.41%	9.54%	2.60%

YD Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YDES YD Bio	0.8557 of 5 stars	$7.81 +5.3%	N/A	N/A	$552.87M	N/A	N/A	15	Gap Down
PHAR Pharming Group	4.1785 of 5 stars	$10.77 -4.4%	$38.67 +259.0%	-31.1%	$796.96M	$376.13M	89.75	407	Analyst Revision
DBVT DBV Technologies	3.7781 of 5 stars	$12.17 -3.6%	$48.50 +298.5%	+17.6%	$794.15M	$5.64M	N/A	161	News Coverage Analyst Forecast
ANNX Annexon	3.5918 of 5 stars	$3.87 -7.4%	$15.14 +291.3%	+38.9%	$792.44M	N/A	N/A	92	Analyst Forecast
VSTM Verastem	3.073 of 5 stars	$8.18 -2.3%	$13.83 +69.1%	-8.8%	$758.02M	$30.91M	N/A	102	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YDES) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

YD Bio (YDES) Competitors

YDES vs. PHAR, DBVT, ANNX, VSTM, and NVCT

How does YD Bio compare to Pharming Group?

Summary

How does YD Bio compare to DBV Technologies?

Summary

How does YD Bio compare to Annexon?

Summary

How does YD Bio compare to Verastem?

Summary

How does YD Bio compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES vs. The Competition

YD Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

YD Bio (YDES) Competitors

YDES vs. PHAR, DBVT, ANNX, VSTM, and NVCT

How does YD Bio compare to Pharming Group?

Do insiders and institutionals have more ownership in YDES or PHAR?

Which has preferable earnings and valuation, YDES or PHAR?

Does the media refer more to YDES or PHAR?

Is YDES or PHAR more profitable?

Do analysts recommend YDES or PHAR?

Summary

How does YD Bio compare to DBV Technologies?

Does the media refer more to DBVT or YDES?

Do analysts rate DBVT or YDES?

Is DBVT or YDES more profitable?

Which has preferable earnings & valuation, DBVT or YDES?

Do insiders and institutionals hold more shares of DBVT or YDES?

Summary

How does YD Bio compare to Annexon?

Does the media refer more to YDES or ANNX?

Is YDES or ANNX more profitable?

Do analysts rate YDES or ANNX?

Which has stronger valuation & earnings, YDES or ANNX?

Summary

How does YD Bio compare to Verastem?

Which has preferable valuation and earnings, VSTM or YDES?

Is VSTM or YDES more profitable?

Do insiders & institutionals believe in VSTM or YDES?

Do analysts rate VSTM or YDES?

Does the media refer more to VSTM or YDES?

Summary

How does YD Bio compare to Nuvectis Pharma?

Do analysts prefer NVCT or YDES?

Do insiders and institutionals believe in NVCT or YDES?

Does the media refer more to NVCT or YDES?

Which has better earnings and valuation, NVCT or YDES?

Is NVCT or YDES more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES vs. The Competition

YD Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools